Ralpher-JZ valued the stock at "nothing less than $30".... and that was prior to Marine approval without disparaging "ANCHOR study free" Marine label; this action directly place Vascepa at a huge disadvantage compared to Lovaza. Also at this time the FDA withheld NCE out of indecision...than delayed it for spite.
If R-I is successful and Amarin can uphold patents via ITC action the stock is worth greater than $150 per share.
News 
Market Data 
Discover 
AI
